Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608526 | 0.85 | MEN1 (0.58) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL11310154 | 0.81 | MEN1 (0.64) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL12251346 | 0.81 | MEN1 (0.58) | MEN1KMT2AATMMAPTSMN1; SMN2 | |
| SCHEMBL12251351 | 0.79 | KMT2A (0.52) | MEN1KMT2AMAPTSMN1; SMN2RAB9A | |
| SCHEMBL7433315 | 0.78 | MEN1 (0.61) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL2125287 | 0.78 | CA12 (0.67) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL2124037 | 0.78 | MEN1 (0.60) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL2123271 | 0.77 | MEN1 (0.56) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL23975950 | 0.77 | MEN1 (0.59) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL2125145 | 0.77 | MEN1 (0.63) | MEN1KMT2AATMMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | MEN1 1146/4885KMT2A 679/4885ATM 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.